Market Cap
$21.2B
GMAB
GENMAB A/S
$34.47 ▼ -0.22%
Prev close $34.55Market cap$21.2B
ConsensusStrong Buy
12-mo target$39.05 (+13.3%)
▲ Bullish
Analyst conviction 8/10
High Impact Filing (7/10)15 New Institutional Positions10 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on GMAB right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Strong Buy (81%)
Inst. Holders
50 funds
Inst. Value
$1.8B
Inst. Activity
15 buys / 10 sells
SEC Reports
13
Price chart 30d +0.8%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 short_volume
Sep 9, 2026 SEC Short Volume: GMAB — 56.4% short (1.4M / 2.5M)
Short: 1,396,961 | Exempt: 39,764 | TRF Vol: 2,478,305 | Short Ratio: 56.4% | Off-exchange volume (d
Genmab A/S filed a 6-K convening an Extraordinary General Meeting on October 7, 2026, to seek shareholder approval of th
6-K — Impact 2/10
Genmab A/S filed its updated Articles of Association on August 11, 2026, via a Form 6-K on August 12, 2026. The filing i
6-K — Impact 2/10
Genmab filed a 6-K reporting a routine capital increase of 24,592 shares from employee warrant exercises, raising approx
6-K — Impact 2/10
Jun 30, 2026 Inst.
CITADEL ADVISORS LLC — NEW
2,475,991 shares ($68.0M)
Jun 30, 2026 Inst.
Qube Research & Technologies — DOUBLED
1,689,284 shares ($46.4M)
Jun 26, 2024 Event
EPKINLY
Supplemental Approval — Efficacy — EPCORITAMAB-BYSP — INJECTABLE — SUBCUTANEOUS
Analyst ratings buy % +37.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
81% rate it Buy or better · 27 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 14, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 7, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| Jul 22, 2026 | TD Cowen | UPGRADE | Buy | 56% |
| Jul 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Jun 23, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Apr 30, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 5 | 17 | 3 | 1 | 1 | 81% | |
| Aug 1, 2026 | 6 | 15 | 3 | 1 | 1 | 81% | |
| Jul 1, 2026 | 6 | 13 | 4 | 1 | 1 | 76% | |
| Jun 1, 2026 | 5 | 14 | 4 | 1 | 1 | 76% | |
| May 1, 2026 | 5 | 14 | 6 | 1 | 1 | 70% | |
| Apr 1, 2026 | 5 | 12 | 8 | 1 | 1 | 63% | |
| Mar 1, 2026 | 5 | 11 | 8 | 1 | 1 | 62% | |
| Feb 1, 2026 | 4 | 12 | 8 | 1 | 1 | 62% |
Price targets
Where 10 covering analysts think GMAB trades over the next 12 months.
$39.05 +13.3% upside Buy
Current$34.48 Low$32.00 Median$40.00 High$45.00 10 analysts
$32.00$45.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
13 SEC filing reports analyzed · 3 bullish, 1 bearish, 0 mixed, 9 neutral · avg impact 3.2/10.
NEUTRAL6-K2/10
Genmab A/S filed a 6-K convening an Extraordinary General Meeting on October 7, 2026, to seek shareh
Sep 9, 2026
NEUTRAL6-K2/10
Genmab A/S filed its updated Articles of Association on August 11, 2026, via a Form 6-K on August 12
Aug 12, 2026
NEUTRAL6-K2/10
Genmab filed a 6-K reporting a routine capital increase of 24,592 shares from employee warrant exerc
Aug 11, 2026
BULLISH6-K6/10
Genmab reported strong H1 2026 results with revenue up 25% YoY to $2,051M, driven by DARZALEX and Ke
Aug 6, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
short_volume
Short Volume: GMAB — 56.4% short (1.4M / 2.5M)
Short: 1,396,961 | Exempt: 39,764 | TRF Vol: 2,478,305 | Short Ratio: 56.4% | Off-exchange volume (dark pool + OTC)
Sep 30, 2026
Clinical Trial
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
Phase Phase 2 — TERMINATED
Sep 30, 2026
short_volume
Short Volume: GMAB — 72.7% short (1.8M / 2.5M)
Short: 1,795,346 | Exempt: 37,916 | TRF Vol: 2,468,730 | Short Ratio: 72.7% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
short_volume
Short Volume: GMAB — 72.1% short (1.3M / 1.8M)
Short: 1,295,230 | Exempt: 35,207 | TRF Vol: 1,796,455 | Short Ratio: 72.1% | Off-exchange volume (dark pool + OTC)
Sep 28, 2026
short_volume
Short Volume: GMAB — 70.7% short (0.6M / 0.9M)
Short: 648,429 | Exempt: 41,628 | TRF Vol: 917,686 | Short Ratio: 70.7% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.34 | $0.24–$0.41 | -47.8% | -4.0% | 2↑ 2↓ | $7.9B | 5 |
| Next Q | $0.30 | $0.19–$0.41 | 541.7% | +5.6% | 2↑ 2↓ | $8.0B | 5 |
| Current FY | $1.18 | $1.18–$1.18 | -33.4% | +4.4% | 2↑ 0↓ | $29.1B | 1 |
| Next FY | $1.53 | $1.53–$1.53 | 29.7% | -3.8% | 1↑ 1↓ | $33.8B | 1 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.337 | — |
| 7d ago | $0.337 | — |
| 30d ago | $0.352 | -0.014 |
| 60d ago | $0.347 | -0.010 |
| 90d ago | $0.311 | +0.026 |
Institutional ownership
Which big funds own GMAB (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $1.8B total value (67,048,062 shares) as of 2026-Q2. Top holders: NOMURA, Orbis, ALLIANCEBERNSTEIN. Net buying activity: 15 institutions added/increased vs 10 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| NOMURA ASSET MANAGEMENT CO LTD | 0 | $0.00 | 0.0% | — |
| Orbis Allan Gray Ltd | 11,368,161 | $312.3M | 17.0% | — |
| ALLIANCEBERNSTEIN L.P. | 8,644,877 | $231.9M | 12.6% | — |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 4,975,324 | $136.7M | 7.4% | — |
| BlackRock, Inc. | 4,671,252 | $128.3M | 7.0% | — |
| RENAISSANCE TECHNOLOGIES LLC | 3,517,850 | $96.6M | 5.3% | ADD +26.4% |
| TWO SIGMA INVESTMENTS, LP | 3,506,843 | $96.3M | 5.2% | — |
| HARDING LOEVNER LP | 3,086,318 | $86.9M | 4.7% | — |
| FIRST TRUST ADVISORS LP | 2,756,522 | $75.7M | 4.1% | ADD +84.3% |
| CITADEL ADVISORS LLC | 2,475,991 | $68.0M | 3.7% | NEW |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| CITADEL ADVISORS LLC | NEW | — | 2,475,991 | — | $68.0M |
| Qube Research & Technologies Ltd | DOUBLED | 677,346 | 1,689,284 | +149.4% | $46.4M |
| MORGAN STANLEY | TRIM | 2,184,701 | 1,630,161 | -25.4% | $44.8M |
| GOLDMAN SACHS GROUP INC | ADD | 931,259 | 1,279,231 | +37.4% | $35.1M |
| UBS Group AG | DOUBLED | 298,132 | 961,053 | +222.4% | $26.4M |
| MARSHALL WACE, LLP | DOUBLED | 15,000 | 829,659 | +5431.1% | $22.8M |
| JPMORGAN CHASE & CO | DOUBLED | 222,607 | 744,815 | +234.6% | $19.4M |
| JANE STREET GROUP, LLC | ADD | 98,432 | 164,743 | +67.4% | $4.5M |
| Schonfeld Strategic Advisors LLC | DOUBLED | 13,467 | 141,353 | +949.6% | $3.9M |
| Quadrature Capital Ltd | DOUBLED | 33,399 | 78,569 | +135.2% | $2.2M |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for GMAB.
Shares short
4,920,530
Settlement Sep 15, 2026
Change vs prior
-28.0%
Semi-monthly cycle
Days to cover
3.2
At avg daily volume
Of shares outstanding
≈3.8%
Estimate — not % of float
All GMAB filing & press-release reports (13)
- 6-K reportSep 9, 2026
- 6-K reportAug 12, 2026
- 6-K reportAug 11, 2026
- 6-K reportAug 6, 2026
- 6-K reportJul 15, 2026
- 6-K reportJun 29, 2026
- 6-K reportJun 17, 2026
- 6-K reportJun 16, 2026
- 6-K reportJun 15, 2026
- 6-K reportJun 15, 2026
- 6-K reportJun 11, 2026
- INST-CLUSTER reportJun 11, 2026
- INST-CLUSTER reportFeb 28, 2026